Susquehanna International Group’s GT Biopharma GTBP Stock Holding History

Susquehanna International Group’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-404	Closed	-$23.1K	–	12601
2024 Q3	$23.1K	Sell	404 -355	-47%	-$21.2K	﹤0.01%	11594
2024 Q2	$53.7K	Buy	+759	New	+$67.9K	﹤0.01%	11380
2023 Q4	–	Sell	-19	Closed	-$3.36K	–	12719
2023 Q3	$3.36K	Sell	19 -9	-32%	-$1.86K	﹤0.01%	11819
2023 Q2	$6.63K	Buy	+28	New	+$7.26K	﹤0.01%	11805
2023 Q1	–	Sell	-18	Closed	-$11.8K	–	12928
2022 Q4	$11.8K	Buy	+18	New	+$22.5K	﹤0.01%	11908
2022 Q3	–	Sell	-59	Closed	-$133K	–	13547
2022 Q2	$133K	Buy	59 +34	+136%	+$64.4K	﹤0.01%	11176
2022 Q1	$54K	Sell	25 -49	-66%	-$108K	﹤0.01%	12277
2021 Q4	$170K	Buy	74 +12	+19%	+$44.9K	﹤0.01%	11641
2021 Q3	$312K	Buy	+62	New	+$466K	﹤0.01%	10513

Other funds holding GTBP

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Susquehanna International Group's GTBP Position: Q4 2024 in Review

Susquehanna International Group sold out of GT Biopharma (GTBP) in Q4 2024, closing a stake of 404 shares — an estimated $23.1K sold.

Susquehanna International Group first reported a position in GTBP in Q3 2021 and held it in 9 quarters. The position peaked at $312K in Q3 2021. 13 funds tracked by Wall St. Rank hold GTBP as of Q4 2024.

Susquehanna International Group reported no remaining GT Biopharma position as of Q4 2024 after selling out during the quarter.
Susquehanna International Group sold 404 GT Biopharma shares in Q4 2024, an estimated $23.1K.
Susquehanna International Group first reported a position in GT Biopharma in Q3 2021 and held it in 9 quarters.
Susquehanna International Group's GT Biopharma position peaked at $312K in Q3 2021.
13 funds tracked by Wall St. Rank held GT Biopharma as of Q4 2024.

Based on Susquehanna International Group's 13F filing for Q4 2024, filed 14 Feb 2025.